BRPI0412430A - polipeptìdeo agonista do receptor de zot e zonulina - Google Patents

polipeptìdeo agonista do receptor de zot e zonulina

Info

Publication number
BRPI0412430A
BRPI0412430A BRPI0412430-8A BRPI0412430A BRPI0412430A BR PI0412430 A BRPI0412430 A BR PI0412430A BR PI0412430 A BRPI0412430 A BR PI0412430A BR PI0412430 A BRPI0412430 A BR PI0412430A
Authority
BR
Brazil
Prior art keywords
zot
agonist polypeptide
agonist
receptor agonist
polypeptide
Prior art date
Application number
BRPI0412430-8A
Other languages
English (en)
Inventor
Alessio Fasano
Stefanie N Vogel
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of BRPI0412430A publication Critical patent/BRPI0412430A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47K—SANITARY EQUIPMENT; ACCESSORIES THEREFOR, e.g. TOILET ACCESSORIES
    • A47K10/00—Body-drying implements; Toilet paper; Holders therefor
    • A47K10/24—Towel dispensers; Toilet paper dispensers
    • A47K10/32—Dispensers for paper towels or toilet paper
    • A47K10/42—Dispensers for paper towels or toilet paper dispensing from a store of single sheets, e.g. stacked
    • A47K10/424—Dispensers for paper towels or toilet paper dispensing from a store of single sheets, e.g. stacked dispensing from the bottom part of the dispenser
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47K—SANITARY EQUIPMENT; ACCESSORIES THEREFOR, e.g. TOILET ACCESSORIES
    • A47K10/00—Body-drying implements; Toilet paper; Holders therefor
    • A47K10/24—Towel dispensers; Toilet paper dispensers
    • A47K10/32—Dispensers for paper towels or toilet paper
    • A47K10/42—Dispensers for paper towels or toilet paper dispensing from a store of single sheets, e.g. stacked
    • A47K10/426—Dispensers for paper towels or toilet paper dispensing from a store of single sheets, e.g. stacked dispensing from the front or sides of the dispenser
    • A47K10/427—Dispensers for paper towels or toilet paper dispensing from a store of single sheets, e.g. stacked dispensing from the front or sides of the dispenser with means for urging the whole stack towards the dispensing opening, e.g. a spring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/08—Containers or packages with special means for dispensing contents for dispensing thin flat articles in succession
    • B65D83/0805—Containers or packages with special means for dispensing contents for dispensing thin flat articles in succession through an aperture in a wall
    • B65D83/0811—Containers or packages with special means for dispensing contents for dispensing thin flat articles in succession through an aperture in a wall with means for assisting dispensing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65H—HANDLING THIN OR FILAMENTARY MATERIAL, e.g. SHEETS, WEBS, CABLES
    • B65H23/00—Registering, tensioning, smoothing or guiding webs
    • B65H23/04—Registering, tensioning, smoothing or guiding webs longitudinally
    • B65H23/18—Registering, tensioning, smoothing or guiding webs longitudinally by controlling or regulating the web-advancing mechanism, e.g. mechanism acting on the running web
    • B65H23/188—Registering, tensioning, smoothing or guiding webs longitudinally by controlling or regulating the web-advancing mechanism, e.g. mechanism acting on the running web in connection with running-web
    • B65H23/1882—Registering, tensioning, smoothing or guiding webs longitudinally by controlling or regulating the web-advancing mechanism, e.g. mechanism acting on the running web in connection with running-web and controlling longitudinal register of web
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Mechanical Engineering (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)

Abstract

"POLIPEPTìDEO AGONISTA DO RECEPTOR DE ZOT E ZONULINA". Foi identificado um polipeptídeo agonista de uma proteina receptora. O agonista pode ser usado tendo em vista facilitar a absorção de droga e de antígeno. Vias adequadas de administração incluem, a oral, nasal, transdérmica e intravenosa. As formulações farmacêuticas podem compreender um agente terapêutico ou um agente imunogênico em combinação com o polipeptídeo agonista.
BRPI0412430-8A 2003-07-15 2004-07-15 polipeptìdeo agonista do receptor de zot e zonulina BRPI0412430A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48788903P 2003-07-15 2003-07-15
PCT/US2004/022753 WO2005010022A2 (en) 2003-07-15 2004-07-15 Agonist polypeptide of receptor for zot and zonulin

Publications (1)

Publication Number Publication Date
BRPI0412430A true BRPI0412430A (pt) 2006-09-05

Family

ID=34102727

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412430-8A BRPI0412430A (pt) 2003-07-15 2004-07-15 polipeptìdeo agonista do receptor de zot e zonulina

Country Status (12)

Country Link
US (3) US7294689B2 (pt)
EP (1) EP1648917A4 (pt)
JP (1) JP2007534621A (pt)
KR (2) KR100858553B1 (pt)
CN (1) CN1852919A (pt)
AU (1) AU2004259705B2 (pt)
BR (1) BRPI0412430A (pt)
CA (1) CA2531491A1 (pt)
IL (1) IL172939A0 (pt)
RU (1) RU2006101992A (pt)
WO (1) WO2005010022A2 (pt)
ZA (1) ZA200600086B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038843A1 (en) * 2006-08-11 2008-02-14 University Of Maryland - Baltimore Method of diagnosing celiac disease
AR053661A1 (es) * 2005-01-14 2007-05-16 Univ Maryland Peptido para entregar vacunas via mucosas
DK1993357T3 (da) * 2006-02-09 2014-04-22 Alba Therapeutics Corp Formuleringer af en tight junction effektor
TW200738269A (en) * 2006-02-09 2007-10-16 Univ Maryland Oral delivery of therapeutic agents using tight junction agonists
TW200810773A (en) * 2006-04-19 2008-03-01 Alba Therapeutics Corp Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
WO2007134241A2 (en) * 2006-05-11 2007-11-22 University Of Maryland Baltimore Nasal delivery of therapeutic agents using tight junction agonists
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) * 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20100144646A1 (en) * 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
WO2009023311A2 (en) * 2007-05-07 2009-02-19 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
WO2009015382A2 (en) * 2007-07-26 2009-01-29 Alba Therapeutics Corporation Novel peptides that enhance tight junction permeability
WO2009137436A2 (en) * 2008-05-05 2009-11-12 Alba Therapeutics Corporation Peptide conjugates
KR101470793B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 흡수촉진제로서의 펩타이드와 이를 포함하는 조성물
CN107281487B (zh) * 2017-06-29 2020-10-09 江苏省农业科学院 一种兽用疫苗佐剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5827534A (en) * 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5912323A (en) * 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5864014A (en) * 1997-02-20 1999-01-26 University Of Maryland At Baltimore Zonula occludens toxin receptor
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6228584B1 (en) * 1997-09-02 2001-05-08 Smithkline Beecham Corporation DexB
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
JP2003534287A (ja) * 2000-05-19 2003-11-18 ユニバーシティ・オブ・メリーランド， ボルティモア 糖尿病発症を予防または遅延させるためのゾヌリンのペプチドアンタゴニストの使用方法
WO2003066859A2 (en) 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier

Also Published As

Publication number Publication date
US7777001B2 (en) 2010-08-17
CN1852919A (zh) 2006-10-25
WO2005010022A3 (en) 2006-07-06
WO2005010022A2 (en) 2005-02-03
AU2004259705A1 (en) 2005-02-03
RU2006101992A (ru) 2007-09-20
AU2004259705B2 (en) 2009-04-23
KR20060037351A (ko) 2006-05-03
US20050059593A1 (en) 2005-03-17
US7294689B2 (en) 2007-11-13
KR20080056318A (ko) 2008-06-20
US20080113918A1 (en) 2008-05-15
ZA200600086B (en) 2007-01-31
CA2531491A1 (en) 2005-02-03
KR100858553B1 (ko) 2008-09-12
EP1648917A4 (en) 2008-11-12
IL172939A0 (en) 2006-06-11
EP1648917A2 (en) 2006-04-26
US20060276403A1 (en) 2006-12-07
JP2007534621A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ID29181A (id) Kombinasi formoterol dan garam tiotropium
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
EP2335727A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
DK0710479T3 (da) Anvendelse af en serotoninagonist sammen med en tachykininreceptorantagonist til fremstilling af et medikament til behandli
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
DK1173476T3 (da) Funktionelle sojabönneproteiner
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.